<DOC>
	<DOCNO>NCT02507102</DOCNO>
	<brief_summary>This feasibility study assess effect Nativis Voyager therapy patient recurrent GBM either fail standard care intolerant therapy . The study enroll treat eleven subject six month . Safety clinical utility evaluate .</brief_summary>
	<brief_title>A Feasibility Study Nativis Voyager™ System Patients With Recurrent Glioblastoma Multiforme ( GBM ) Australia</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . Subject histologically confirm diagnosis GBM . 2 . Subject fail intolerant radiotherapy . 3 . Subjects fail intolerant temozolomide therapy . 4 . Subject progressive disease least one measureable lesion MRI CT. 5 . Subject least 18 year age . 6 . Subject KPS ≥ 60 . 7 . Subject adequate organ marrow function . 8 . Subject provide sign informed consent . 1 . Subject life expectancy less eight week 2 . Subject receive investigational therapy within last 28 day . 3 . Subject receive surgery within last two week fully prior surgery . 4 . Subject clinically significant electrolyte abnormality . 5 . Subject active implantable ( e.g. , neurostimulator , pacemaker ) electromagnetic device . 6 . Subject metal implant , include stent , head neck incompatible MRI . 7 . Subject know HIV positive . 8 . Subject pregnant , nursing intend become pregnant study period . 9 . Subject participate investigational research . 10 . Subject condition discretion investigator would preclude participation study . 11 . Subject unable unwilling comply protocolrequired followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>